# OnCo record nct07310784 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07310784/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07310784", "NCT07310784" ;
  schema:name "A Phase II Trial of LM103 in Advanced Melanoma"@en ;
  schema:description "A phase 2 trial of Dacarbazine, Temozolomide, Paclitaxel / nab-paclitaxel in melanoma, run by Suzhou BlueHorse Therapeutics Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07310784/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07310784> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2025-12-16" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/advanced-melanoma/> ;
  onco:drugs <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/> ;
  onco:companies <https://onco.cc/companies/suzhou-bluehorse-therapeutics/> .